High Dose L-Carnitine Improves Immunologic and Metabolic Parameters in Aids Patients

References

• Carnitine deficiency. Lancet 1990; 335: 631–33, Editorial
   PubMed Web of Science ®Google Scholar
• Hommes M JT, Romijn J A, Endert E, et al. Basal fuel homeostasis in symptomatic human immunodeficiency virus infection. Clin Sci 1991; 80: 359–65
   Web of Science ®Google Scholar
• Stein T P, Nutinsky C, Condolucci D, et al. Protein and energy substrate metabolism in AIDS patients. Metabolism 1990; 39: 876–81
   PubMed Web of Science ®Google Scholar
• Aguilar J J, Anel A, Torres J M, et al. Changes in lipid composition of human peripheral blood lymphocytes infected by HIV. AIDS Res Hum Retrovir 1991; 7: 761–65
   PubMed Web of Science ®Google Scholar
• Apostolov K, Barker W, Wood C B, et al. Fatty acid saturation index in peripheral blood cell membranes in AIDS patients. Lancet 1987; 1: 695
   PubMed Web of Science ®Google Scholar
• Apostolov K, Barker W, Galpin S A, et al. Syncitia formation in HIV-1 infected cells is associated with an increase in cellular oleic acid. FEBS Lett 1989; 250: 241–44
   PubMed Web of Science ®Google Scholar
• Klein A, Mercure L, Gordon P, et al. The effect of HIV-1 infection on the lipid fatty acid content in the membrane of cultured lymphocytes. AIDS 1990; 9: 865–67
   Google Scholar
• De Simone C, Tzantzoglou S, Jirillo E, et al. L-carnitine deficiency in AIDS patients. AIDS 1991; 6: 203–05
   Web of Science ®Google Scholar
• De Simone C, Tzantzoglou S, Moretti S, et al. Carnitine deficiency in HIV-infected subjects: carnitine modulates S and G2-M phases lymphocytes. Ann NY Acad Sci USA 1992, (in press)
   Google Scholar
• Deufel T. Determination of L-carnitine in biological fluids and tissues. J Clin Chem Clin Biochem 1990; 28: 307–11
   PubMedGoogle Scholar
• McGarry J D, Foster D W. Free and esterified carnitine: ra-diomethod. Methods of Enzymatic Analysis, J Bergmejer, G M Weinheim. Verlag Chemie GmBhm. 1983; vol. VIII: 474–81
   Google Scholar
• Mastroianni C M, Paoletti F, Vullo V, et al. β-microglobulin in asymptomatic HIV-infected patients treated with zidovudine. AIDS 1990; 4: 1297
   PubMed Web of Science ®Google Scholar
• Mastroianni C M, Paoletti F, Vullo V, et al. Tumor Necrosis Factor (TNF) and neurological disorders in HIV infection. J Neurol Neuroimmuno Psy 1992; 55
   Google Scholar
• Krishan A. J Biol Cell 1975; 66: 188–93
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987; 36: 1S
   PubMedGoogle Scholar
• Tripp M E, Shug A L. Plasma carnitine concentrations in car-diomyopathy patients. Biochem Med 1984; 32: 199–206
   PubMedGoogle Scholar
• Bohmer T, Rydning A, Solberg H E. Carnitine levels in human serum in health and disease. Clin Chem Acta 1974; 57: 55–61
   PubMed Web of Science ®Google Scholar
• Epstein J S, Frederick W R, Rook A H. Selective defects in cytomegalovirus-and mitogen-induced lymphocyte proliferation and interferon release in patients with acquired immunodeficiency syndrome. J Infect Dis 1985; 152: 727–53
   PubMed Web of Science ®Google Scholar
• Resch K, Ferber E. Structure and role of phospholipids in the lymphocyte plasma membrane. The Lymphocyte, Structure and Function, J Marchalonis. Marcel Dekker Inc, New York 1987; 171–222
   Google Scholar
• Begin, et al. Arch AIDS Res 1988; 33: 159–66
   Google Scholar
• Lynn W S, Tweedale A, Cloyd M W. Human immunodeficiency virus (HIV-1) cytotoxicity: perturbation of the cell membrane and depression of phospholipid synthesis. Virology 1988; 163: 43–51
   PubMed Web of Science ®Google Scholar
• Bremer J. The role of carnitine in intracellular metabolism. J Clin Chem Clin Biochem 1990; 28: 297–301
   PubMedGoogle Scholar
• Lahdevirta J, Maury C PJ, Teppo A M, et al. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988; 85: 289–91
   PubMed Web of Science ®Google Scholar
• Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease. AIDS 1991; 5: 1405–17
   PubMed Web of Science ®Google Scholar
• Lenardo M J, Baltimore D. NF-kB: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58: 227–229
   PubMed Web of Science ®Google Scholar
• Sherry B, Cerami A. Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J Cell Biol 1988; 107: 1269–77
   PubMed Web of Science ®Google Scholar
• Tracey K J, Cerami A. The role of cachectin/tumor necrosis factor in AIDS. Cancer Cells 1989; 1: 62–3
   PubMed Web of Science ®Google Scholar
• Mildvan D, Machado S G, Wilets I, et al. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992; 339: 453–56
   PubMed Web of Science ®Google Scholar
• Moss A R, Bacchetti P, Osmond D, et al. Seropositivity from HIV and the development of AIDS or AIDS-related condition: three-year follow up of the San Francisco General Hospital cohort. Br Med J 1988; 296: 745–49
   PubMed Web of Science ®Google Scholar
• Oppenheim J J, Ruscetti W F, Faltynek C. Cytokines. Basic and Clinical Immunology, D P Stites, A L Terr. Appleton & Lange, Norwalk 1991; 92–96
   Google Scholar
• Jacobsen M A, Bacchetti P, Kolokathis A, et al. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. Br Med J 1991; 302: 73–78
   PubMedGoogle Scholar
• Krown S E, Niedzwiecki D, Bhalla R B, et al. Relationship and prognostic value of endogenous interferon-α, P2-microglobulin. and neopterin serum levels in patients with Kaposi's sarcoma and AIDS. J Acquir Immun Defic Syndr 1991; 4: 871–80
   PubMed Web of Science ®Google Scholar
• Fahey Jl, Taylor J MG, Detels R, et al. The prognostic value of cellular and serological markers in infection with human immunodeficiency virus type I. N Engl J Med 1990; 322: 166–72
   PubMed Web of Science ®Google Scholar
• Anderson R E, Lang W, Shiboski S, et al. Use of β2-microglobulin level and CD4 count to predict development of acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. Arch Intern Med 1990; 150: 73–7
   PubMedGoogle Scholar